Inflammasomes and metabolic disease

Annual Review of Physiology

Volumn 76, Issue , 2014, Pages 57-78

  Henao Mejia, Jorge ^a   Elinav, Eran ^b   Thaiss, Christoph A ^b   Flavell, Richard A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Inflammasomes; Metabolic syndrome; Obesity; Toll like receptors

Indexed keywords

ANIMALS; HUMANS; IMMUNOLOGIC SURVEILLANCE; INFLAMMASOMES; METABOLIC DISEASES; METABOLIC SYNDROME X; OBESITY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84894196760     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021113-170324     Document Type: Review

References (133)

1. Medzhitov R. 2009. Approaching the asymptote: 20 years later. Immunity 30:766-755
2. Medzhitov R. 2008. Origin and physiological roles of inflammation. Nature 454:428-355
3. Strowig T, Henao-Mejia J, Elinav E, Flavell R. 2012. Inflammasomes in health and disease. Nature 481:278-866
4. Martinon F, Mayor A,Tschopp J. 2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27:229-655
5. Wen H, Ting JP, O'Neill LA. 2012. A role for the NLRP3 inflammasome in metabolic diseases -did Warburg miss inflammation? Nat. Immunol. 13:352-577
6. Schroder K, Zhou R, Tschopp J. 2010. The NLRP3 inflammasome: a sensor for metabolic danger? Science 327:296-3000
7. Henao-Mejia J, Elinav E, Strowig T, Flavell RA. 2012. Inflammasomes: far beyond inflammation. Nat. Immunol. 13:321-244
8. Franchi L, Eigenbrod T, NunezG. 2009. Cutting edge:TNF-mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J. Immunol. 183:792-966
9. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, et al. 2009. Cutting edge: NF-B activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183:787-911
10. Bauernfeind F, Bartok E, Rieger A, Franchi L, Nunez G, Hornung V. 2011. Cutting edge: Reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J. Immunol. 187:613-177
11. Latz E, Xiao TS, Stutz A. 2013. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13:397-4111
12. Elinav E, Strowig T,Henao-Mejia J, Flavell RA. 2011. Regulation of the antimicrobial response by NLR proteins. Immunity 34:665-799
13. Jin T, Perry A, Jiang J, Smith P, Curry JA, et al. 2012. Structures of theHIN domain:DNA complexes reveal ligand binding and activationmechanisms of the AIM2 inflammasome and IFI16 receptor. Immunity 36:561-711
14. Hsu LC, Ali SR, McGillivray S, Tseng PH, Mariathasan S, et al. 2008. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1 β secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc. Natl. Acad. Sci. USA 105:7803-88
15. Ferwerda G, Kramer M, de Jong D, Piccini A, Joosten LA, et al. 2008. Engagement of NOD2 has a dual effect on proIL-1 βmRNA transcription and secretion of bioactive IL-1 β. Eur. J. Immunol. 38:184-911
16. Kofoed EM, Vance RE. 2011. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477:592-955
17. Zhao Y, Yang J, Shi J, Gong YN, Lu Q, et al. 2011. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477:596-6000
18. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, et al. 2010. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 11:395-4022
19. Khare S,DorfleutnerA,Bryan NB,Yun C, Radian AD, et al. 2012. An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Immunity 36:464-766
20. Latz E. 2010. The inflammasomes: mechanisms of activation and function. Curr. Opin. Immunol. 22:28-333
21. Koizumi Y, Toma C, Higa N, Nohara T, Nakasone N, Suzuki T. 2012. Inflammasome activation via intracellular NLRs triggered by bacterial infection. Cell Microbiol. 14:149-544
22. Ichinohe T, Pang IK, Iwasaki A. 2010. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat. Immunol. 11:404-100
23. Gomes MT, Campos PC, Oliveira FS, Corsetti PP, Bortoluci KR, et al. 2013. Critical role of ASC inflammasomes and bacterial type IV secretion system in caspase-1 activation and host innate resistance to Brucella abortus infection. J. Immunol. 190:3629-388
24. Sander LE, Davis MJ, Boekschoten MV, Amsen D, Dascher CC, et al. 2011. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 474:385-899
25. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, et al. 2009. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl. Acad. Sci. USA 106:20388-933
26. Duncan JA, Bergstralh DT, Wang Y, Willingham SB, Ye Z, et al. 2007. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc. Natl. Acad. Sci. USA 104:8041-466
27. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, et al. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228-322
28. Zhong Z, Zhai Y, Liang S, Mori Y, Han R, et al. 2013. TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat. Commun. 4:16111
29. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, et al. 2013. Succinate is an inflammatory signal that induces IL-1 βthrough HIF-1?. Nature 496:238-422
30. Pazar B, Ea HK, Narayan S, Kolly L, Bagnoud N, et al. 2011. Basic calcium phosphate crystals induce monocyte/macrophage IL-1 βsecretion through the NLRP3 inflammasome in vitro. J. Immunol. 186:2495-5022
31. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-411
32. So A, De Smedt T, Revaz S, Tschopp J. 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9:R288
33. Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, et al. 2013. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1 βsecretion. J. Clin. Investig. 123:236-466
34. Knauf F, Asplin JR, Granja I, Schmidt IM, Moeckel GW, et al. 2013. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 84:895-9011
35. Jin C, Frayssinet P, Pelker R, Cwirka D, Hu B, et al. 2011. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite- associated arthropathy. Proc. Natl. Acad. Sci. USA 108:14867-722
36. Denoble AE, Huffman KM, Stabler TV, Kelly SJ, Hershfield MS, et al. 2011. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc. Natl. Acad. Sci. USA 108:2088-933
37. So A, Busso N. 2011. Osteoarthritis: crystal-gazing into the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 7:688-899
38. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, et al. 2008. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol. 9:857-655
39. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, et al. 2013. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493:674-788
40. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, et al. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9:847-566
41. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, et al. 2008. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. USA 105:9035-400
42. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320:674-777
43. Li H, Willingham SB, Ting JP, Re F. 2008. Cutting edge: Inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181:17-211
44. Kool M, Petrilli V, DeSmedt T, Rolaz A, Hammad H, et al. 2008. Cutting edge:Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181:3755-599
45. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. 2008. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453:1122-266
46. Spreafico R, Ricciardi-Castagnoli P, Mortellaro A. 2010. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur. J. Immunol. 40:638-422
47. Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, et al. 2011. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 17:479-877
48. Misawa T, Takahama M, Kozaki T, Lee H, Zou J, et al. 2013. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol. 14:454-600
49. Shenoy AR, Wellington DA, Kumar P, Kassa H, Booth CJ, et al. 2012. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science 336:481-855
50. Dinarello CA, Simon A, van der Meer JW. 2012. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11:633-522
51. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A. 1999. The secretory route of the leaderless protein interleukin 1 β involves exocytosis of endolysosome-related vesicles. Mol. Biol. Cell 10:1463-755
52. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A. 2004. Phospholipases C and A2 control lysosome-mediated IL-1 βsecretion: implications for inflammatory processes. Proc. Natl. Acad. Sci. USA 101:9745-500
53. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. 2001. Rapid secretion of interleukin-1 βby microvesicle shedding. Immunity 15:825-355
54. Pelegrin P, Barroso-Gutierrez C, Surprenant A. 2008. P2X7 receptor differentially couples to distinct release pathways for IL-1 βin mouse macrophage. J. Immunol. 180:7147-577
55. Bergsbaken T, Fink SL, Cookson BT. 2009. Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 7:99-1099
56. Sagulenko V, Thygesen SJ, Sester DP, Idris A, Cridland JA, et al. 2013. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ. 20:1149-600
57. Zychlinsky A, Prevost MC, Sansonetti PJ. 1992. Shigella flexneri induces apoptosis in infected macrophages. Nature 358:167-699
58. Watson PR, Gautier AV, Paulin SM, Bland AP, Jones PW, Wallis TS. 2000. Salmonella enterica serovars Typhimurium and Dublin can lyse macrophages by a mechanism distinct from apoptosis. Infect. Immun. 68:3744-477
59. Li J, McQuade T, Siemer AB, Napetschnig J,Moriwaki K, et al. 2012. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 150:339-500
60. Riedl SJ, Salvesen GS. 2007. The apoptosome: signalling platform of cell death. Nat. Rev. Mol. Cell Biol. 8:405-133
61. Monack DM, Raupach B, Hromockyj AE, Falkow S. 1996. Salmonella typhimurium invasion induces apoptosis in infected macrophages. Proc. Natl. Acad. Sci. USA 93:9833-388
62. Cookson BT, BrennanMA. 2001. Pro-inflammatory programmed cell death. Trends Microbiol. 9:113-144
63. Zhou R, Yazdi AS, Menu P, Tschopp J. 2011. A role for mitochondria in NLRP3 inflammasome activation. Nature 469:221-255
64. Gregor MF, Hotamisligil GS. 2011. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29:415-455
65. Samuel VT, Shulman GI. 2012. Mechanisms for insulin resistance: common threads and missing links. Cell 148:852-711
66. Feve B, Bastard JP. 2009. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5:305-111
67. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, et al. 2006. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat. Med. 12:650-566
68. Am. Diet. Assoc. 2013. Economic costs of diabetes in the US in 2012. Diabetes Care 36:1033-466
69. Bunout D, Munoz C, Lopez M, de la Maza MP, Schlesinger L, et al. 1996. Interleukin 1 and tumor necrosis factor in obese alcoholics compared with normal-weight patients. Am. J. Clin.Nutr. 63:373-766
70. Pickup JC, Crook MA. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-488
71. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. 1999. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-355
72. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose expression of tumor necrosis factor-: direct role in obesity-linked insulin resistance. Science 259:87-911
73. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. 1995. Increased adipose tissue expression of tumor necrosis factor-in human obesity and insulin resistance. J. Clin. Investig. 95:2409-155
74. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. 1995. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Investig. 95:2111-199
75. Aguirre V, Uchida T, Yenush L, Davis R,White MF. 2000. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J. Biol. Chem. 275:9047-544
76. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-and obesity-induced insulin resistance. Science 271:665-688
77. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, et al. 2006. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Investig. 116:115-244
78. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, et al. 2006. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Investig. 116:1494-5055
79. Konner AC, Bruning JC. 2011. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol. Metab. 22:16-233
80. Donath MY, Shoelson SE. 2011. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11:98-1077
81. Tanti JF, Ceppo F, Jager J, Berthou F. 2012. Implication of inflammatory signaling pathways in obesityinduced insulin resistance. Front. Endocrinol. 3:1811
82. Saberi M, Woods NB, de Luca C, Schenk S, Lu JC, et al. 2009. Hematopoietic cell-specific deletion of Toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 10:419-299
83. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Investig. 116:3015-255
84. Vandanmagsar B, Youm YH, Ravussin A,Galgani JE, Stadler K, et al. 2011. TheNLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17:179-888
85. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, et al. 2010. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12:593-6055
86. Wen H, Gris D, Lei Y, Jha S, Zhang L, et al. 2011. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12:408-155
87. Jager J, Gremeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. 2007. Interleukin-1 β-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148:241-511
88. Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, et al. 2009. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabeticGKrat. Proc.Natl. Acad. Sci. USA106:13998-40033
89. Osborn O, Gram H, Zorrilla EP, Conti B, Bartfai T. 2008. Insights into the roles of the inflammatory mediators IL-1, IL-18 and PGE2 in obesity and insulin resistance. Swiss Med. Wkly. 138:665-733
90. De Nardo D, Latz E. 2011. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 32:373-799
91. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, et al. 2010. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12:593-6055
92. Dinarello CA, Donath MY, Mandrup-Poulsen T. 2010. Role of IL-1 β in type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 17:314-211
93. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, et al. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356:1517-266
94. Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, et al. 2012. Saturated fatty acid and TLR signaling link βcell dysfunction and islet inflammation. Cell Metab. 15:518-333
95. Seino S. 2001. S20G mutation of the amylin gene is associated with type II diabetes in Japanese. Study Group of Comprehensive Analysis of Genetic Factors in Diabetes Mellitus. Diabetologia 44:906-99
96. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, et al. 2010. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides amechanism for enhanced IL-1 βin type 2 diabetes. Nat. Immunol. 11:897-9044
97. Zhou R, Tardivel A, Thorens B,Choi I,Tschopp J. 2010. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11:136-400
98. Dahlof B. 2010. Cardiovascular disease risk factors: epidemiology and risk assessment. Am. J. Cardiol. 105:A3-99
99. Lau KK, Wong YK, Chan YH, Yiu KH, Teo KC, et al. 2012. Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with type 2 diabetes. Cardiovasc. Diabetol. 11:1011
100. Hansson GK, Hermansson A. 2011. The immune system in atherosclerosis. Nat. Immunol. 12:204-122
101. Ding L, Biswas S, Morton RE, Smith JD, Hay N, et al. 2012. Akt3 deficiency in macrophages promotes foam cell formation and atherosclerosis in mice. Cell Metab. 15:861-722
102. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, et al. 2004. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA 101:10679-844
103. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, et al. 2004. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 10:416-211
104. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, et al. 2007. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ. Res. 100:1589-966
105. Coenen KR, Gruen ML, Lee-Young RS, Puglisi MJ, Wasserman DH, Hasty AH. 2009. Impact of macrophage Toll-like receptor 4 deficiency on macrophage infiltration into adipose tissue and the artery wall in mice. Diabetologia 52:318-288
106. Ding Y, Subramanian S, Montes VN, Goodspeed L, Wang S, et al. 2012. Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 32:1596-6044
107. Madan M, Amar S. 2008. Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings. PLoS ONE 3:e32044
108. Mullick AE, Tobias PS, Curtiss LK
109. J. Clin. Investig. 115:3149-566
110. Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, et al. 2010. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 12:467-822
111. West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, et al. 2010. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467:972-766
112. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, et al. 2010.NLRP3inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464:1357-611
113. Gage J, Hasu M, Thabet M, Whitman SC. 2012. Caspase-1 deficiency decreases atherosclerosis in apolipoprotein E-null mice. Can. J. Cardiol. 28:222-299
114. Usui F, Shirasuna K, Kimura H, Tatsumi K, Kawashima A, et al. 2012. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis inWestern diet-fed apolipoprotein E-deficient mice. Biochem. Biophys. Res. Commun. 425:162-688
115. Menu P, Pellegrin M, Aubert JF, Bouzourene K, Tardivel A, et al. 2011. Atherosclerosis in ApoEdeficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis. 2:e1377
116. Serfaty L, Lemoine M. 2008. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 34:634-377
117. Henao-Mejia J, Elinav E, Thaiss CA, Flavell RA. 2013. The intestinal microbiota in chronic liver disease. Adv. Immunol. 117:73-977
118. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, et al. 2001. Nonalcoholic steatohepatitis: association of insulin resistance andmitochondrial abnormalities. Gastroenterology 120:1183-922
119. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, et al. 2010. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1 βin mice. Gastroenterology 139:323-34.e77
120. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. 2007. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47:571-799
121. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, et al. 2009. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49:1877-877
122. Boaru SG, Borkham-Kamphorst E, Tihaa L, Haas U, Weiskirchen R. 2012. Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease. J. Inflamm. 9:499
123. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, et al. 2011. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145:745-577
124. Miyake Y, Yamamoto K. 2012. Role of gut microbiota in liver diseases. Hepatol. Res. 43:139-466
125. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al. 2012. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482:179-855
126. Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. 2013. Risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel disease. J. Crohn's Colitis 7:e279-855
127. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. 2011. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54:133-444
128. Zhu Y, Pandya BJ, Choi HK. 2011. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 63:3136-411
129. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, et al. 2010. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62:3064-766
130. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, et al. 2009. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann. Rheum. Dis. 68:1613-177
131. Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, et al. 2011. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann. Rheum. Dis. 70:1264-711
132. Martin WJ, Walton M, Harper J. 2009. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum. 60:281-899
133. Torres R, MacDonald L, Croll SD, Reinhardt J, Dore A, et al. 2009. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann. Rheum. Dis. 68:1602-88